Porustobart clinical trials
Also written HBM4003.
How each study uses porustobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the porustobart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Harbour BioMed (Guangzhou) Co. Ltd. (2) · Harbour BioMed US, Inc. (1) · Solstice Oncology, Inc. (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses porustobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon CancerRecruitingPhase 2Solstice Oncology, Inc.NCT07808151Written as Porustobart
- A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid TumorsCompletedPhase 1Harbour BioMed US, Inc.NCT04135261Written as HBM4003
- A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 AntibodyStatus unknownPhase 1Harbour BioMed (Guangzhou) Co. Ltd.NCT04866485Written as HBM4003 and pembrolizumab
- Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With ToripalimabStatus unknownPhase 1Harbour BioMed (Guangzhou) Co. Ltd.NCT04727164Written as HBM4003 and Triprilimab
Given beside what is tested · 1 — porustobart is usual care or a partner of the new treatment
Codes
What other systems call porustobart · ClinicalTrials.gg INT016955
- UNII (FDA) JJY4JHN685PORUSTOBARTOne source FDA
- NCI Thesaurus C173540PorustobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JJY4JHN685 | PORUSTOBART | One source FDA |
| NCI Thesaurus | C173540 | Porustobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.